Figure 3.

MiR-129-5p directly targets DNMT3A and negatively regulates cell cycle-related proteins. A. Predicted miR-129-5p binding sites in the 3’-UTR of the DNMT3A gene. B. The expression levels of DNMT3A in non-tumor brain tissues (NBTs) and glioma specimens were determined by western blotting; the fold changes were normalized to β-Actin. The NBTs (n=9) were collected from brain trauma surgery. The glioblastoma (GBM) tissues (n=17) were collected from Surgical specimens of patients with primary glioblastoma. Data represent the means ± SD from three independent experiments. (***P<0.001). C. Pearson’s correlation analysis of the relationship between the relative expression levels of miR-129-5p and the relative protein levels of DNMT3A in Clinical tissue samples. D. Wild-type and mutant DNMT3A 3’-UTR reporter constructs. E. Luciferase reporter assays were performed in U87 and LN229 cells co-transfected with the indicated wild-type or mutant 3’-UTR constructs and the miR-129-5p mimic. The data shown are representative of three independent experiments. Data shown are mean ± SD of three independent experiments. (*P<0.05, **P<0.01, ***P<0.001).